AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01116921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactants, Pulmonary
Description: Curosurf®, Chiesi USA, Inc., Cary, NC
Study NCT03429348 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sauna Rehabilitation
Description: Firefighters selected for sauna rehabilitation will spend time in a sauna
Study NCT03040167 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PEC 1 block
Description: Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.
Study NCT03040167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEC 1 block
Description: Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.
Study NCT03040167 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine with epinephrine
Description: Treatment group
Study NCT03040167 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo group
Study NCT03504215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Assigned intervention : 14-week supervised intervention of aerobic and resistance training.
Study NCT01298700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.01% ophthalmic solution
Description: One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
Study NCT01298700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost 0.03% ophthalmic solution
Description: One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
Study NCT02692586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowTriever System
Study NCT04622917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MethylPREDNISolone 40 Mg/mL Injectable Suspension
Description: intramuscular injection
Study NCT04622917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 9 MG/ML Injectable Solution
Description: Intramuscular injection
Study NCT03539107 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde bladder fill
Description: Subjects will have their bladder retrograde filled with 300mL of fluid prior to a voiding trial.
Study NCT03539107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spontaneous void
Description: Subjects will not have retrograde fill of bladder, rather will be required to void 150 mL spontaneously prior to discharge.
Study NCT01150630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1250 mg/mq/day per os for 14 days every 14 days for 6 months
Study NCT01150630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 30 mg/mq every 14 days for 6 months
Study NCT01150630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: 30 mg/mq every 14 days for 6 months
Study NCT01150630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
Study NCT01150630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
Study NCT01690507 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Decitabine
Description: 20 mg/m²/day for 5 days
Study NCT01690507 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Study NCT01690507 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: aclacinomycin
Study NCT01690507 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Granulocyte colony-stimulating factor
Study NCT01690507 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: HLA haploidentical mononuclear cells infusion
Study NCT01838239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
Study NCT00238407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and Cisplatin
Description: Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.
Study NCT00238407 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
Study NCT03239678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% Oxygen
Description: Conventional preoxygenation with 100% oxygen
Study NCT03239678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% Oxygen
Description: preoxygenation with 30% oxygen
Study NCT03239678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 21% Oxygen
Description: preoxygenation with 21% oxygen
Study NCT03239678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40% Oxygen
Description: preoxygenation with 40% oxygen
Study NCT03239678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60% Oxygen
Description: preoxygenation with 60% oxygen
Study NCT03239678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80% Oxygen
Description: preoxygenation with 80% oxygen
Study NCT00913549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)
Study NCT00913549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)
Study NCT01714544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cloderm Cream
Study NCT02037724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplement containing 60 mg iron sulfate
Description: control agent
Study NCT02037724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: supplement containing 60 mg iron sulfate
Description: control agent
Study NCT02037724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron rich food supplement (60 mg iron)
Description: contains 60 mg of iron
Study NCT02037724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: iron rich food supplement (60 mg iron)
Description: contains 60 mg of iron
Study NCT04195139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Participants will receive Nivolumab intravenous infusions (240 mg days 1 and 15 every 28 days for cycles 1-4; then 480 mg day 1 every 28 days for cycles 5-6).
Study NCT04195139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.
Study NCT04195139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Participants will receive temozolomide (TMZ) tablets days 1-5, every 28 days for 6 cycles. TMZ will be dosed at 150mg/m2 for the first cycle. If well tolerated TMZ is then given at 200mg/m2 for cycles 2 - 6.
Study NCT03623945 — intervention group
Intervention type: OTHER
Intervention: Collection of blood
Description: Collection of blood only to look at circulating autoantibodies that recognize breast cancer proteins to potentially be used as a biosensor for identifying patients with increased risk of having breast cancer
Study NCT02037724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iron rich food supplement (10 mg iron)
Description: contains 10 mg iron
Study NCT02037724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: iron rich food supplement (10 mg iron)
Description: contains 10 mg iron
Study NCT02037724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplement containing 10 mg iron sulfate
Description: control agent
Study NCT02037724 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: supplement containing 10 mg iron sulfate
Description: control agent
Study NCT03729050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation Coordinator in Specialist Psychiatry
Description: Rehabilitation Coordinator service in Specialist Psychiatry
Study NCT02697214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Charge HR
Description: Fitbit Charge HR heart rate monitoring device compared to ECG and Polar H7
Study NCT02697214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple Watch
Description: Apple Watch heart rate monitoring device compared to ECG and Polar H7
Study NCT02697214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mio Fuse
Description: Mio Fuse heart rate monitoring device compared to ECG and Polar H7
Study NCT02697214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Basis Peak
Description: Basis Peak heart rate monitoring device compared to ECG and Polar H7
Study NCT04180488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study NCT04180488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Study NCT04180488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non sedating H1-antihistamine
Description: Pharmaceutical form:Tablet Route of administration: oral administration
Study NCT04180488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: non sedating H1-antihistamine
Description: Pharmaceutical form:Tablet Route of administration: oral administration
Study NCT02942277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs25M-EPA
Description: The PpPfs25M and EcEPA lots, both manufactured at Walter Reed Bioproduction facility (Silver Spring, Maryland) in cGMP compliance, were used to manufacture the conjugate. PpPfs25M is a Pichia- expressed recombinant Pfs25 with a molecular mass of 18,713 Daltons.The Pfs25M- EPA was formulated as conjugated Pfs25M in 4 mM PBS to a 2X dilution of the high dose (188 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
Study NCT02597517 — intervention group
Intervention type: DEVICE
Intervention: Digital chromoendoscopy and magnification
Description: After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits
Study NCT01095497 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE
Description: C1 esterase inhibitor (human)
Study NCT03645642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine 5 mg thrice daily
Study NCT03645642 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Albumin
Description: Albumin 20g/l
Study NCT03645642 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Albumin 20g/l
Study NCT03645642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics
Description: Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
Study NCT03645642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diuretics
Description: Diuretics will be continued with an maximum dose of furosemide (160mg) and Aldactone 400 mg.
Study NCT03485443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: %0.9 NaCl 10ml/kg
Description: Fluid administration
Study NCT02942277 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfs230D1M-EPA
Description: The Pfs230D1M-EPA was formulated as conjugated Pfs230D1M in 4 mM PBS to a 2X dilution of the high dose (160 (Micro)g/ml in 0.5 ml volume) in cGMP compliance at Walter Reed Bio-production facility in April 2016 and will be provided as a single use vial.
Study NCT03485443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: %0.9 NaCl 20ml/kg
Description: Fluid administration
Study NCT00004244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Study NCT00004244 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Study NCT03080740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin palmitate hydrochloride dispersible tablet
Description: 300mg, oral after meal, twice daily, a total of 7days
Study NCT03080740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Tablet
Description: 400mg, oral after meal , twice daily, a total of 7days
Study NCT02546648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT02546648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Placebo
Study NCT02546648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin or matching placebo
Description: Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
Study NCT00600093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine
Description: IV Amantadine 200mg \*1/d at the beginning of surgery and 24 hours following surgery
Study NCT05606861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Interventions in Pediatric Nurses
Description: This intervention are structured mindfulness program including meditation and breathing techniques .
Study NCT04102618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: 4.5 × 10e10 TCID50 administered intravenously on Days 1, 2, 8 \& 9
Study NCT04102618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Oral dose of 2.5 mg/day starting on Day 3 for 13 days
Study NCT04102618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200 mg administered intravenously on Day 3
Study NCT04102618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 8mg/kg administered intravenously or 600mg subcutaneously on Day 3
Study NCT02942277 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS01
Description: AS01B adjuvant will also be provided as a single use vial by GSK, 100 microgram/mL MPL and 100microgram/mL QS21 in a liposomal formulation in a volume of 0.625 mL. One dose injected of AS01B corresponds to 50 μg QS21 and 50 μg MPL.
Study NCT00999505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine
Description: Amantadine 200mg twice a day over 12 weeks
Study NCT00999505 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules twice a day over 12 weeks
Study NCT03159585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAEST16001
Description: After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001
Study NCT02731378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietins (EPO)
Description: A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
Study NCT02731378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aggressive iron dextran supplementation
Description: Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
Study NCT02731378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietins (EPO)
Description: Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
Study NCT02731378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained iron dextran supplementation
Description: Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
Study NCT02820077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemospray (Endoscopic treatment with hemostatic powder)
Description: Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards
Study NCT00804453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cartridge blood set
Description: Once a week
Study NCT00804453 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard blood line
Description: Once a week
Study NCT00610168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix TM
Description: Single booster dose of vaccine
Study NCT02557724 — intervention group
Intervention type: PROCEDURE
Intervention: blood samples
Description: liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
Study NCT02557724 — intervention group
Intervention type: PROCEDURE
Intervention: blood samples
Description: liver resection patients will have (3) 3cc. blood samples drawn at specific time points
Study NCT04632277 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Participants will receive a tab water
Study NCT04632277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water with low Mg
Description: Participants will receive Low Mg bottle water (50mg/l)
Study NCT04632277 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water with high Mg
Description: Participants will receive High Mg bottle water (100mg/l)
Study NCT06010797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Showing Pre-treatment photographs of the patient
Description: Extra-oral and intra-oral dental photographs of patients were taken before starting Orthodontic treatment. Experimental group were shown their photographs while control group were not shown their photographs.
Study NCT03021811 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: KLOX LumiHeal BioPhotonic System
Description: Real-life use of KLOX LumiHeal BioPhotonic System in combination with standard of care.
Study NCT01587885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg
Description: Capsules, orally
Study NCT01587885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg
Description: Capsules, orally
Study NCT01587885 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20 mg
Description: Tablets, orally
Study NCT01587885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Description: Tablets, orally
Study NCT02246738 — intervention group
Intervention type: OTHER
Intervention: Blood Collection
Study NCT02942277 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: ENGERIX-B (hepatitis B vaccine; recombinant): is a sterile suspension of noninfectious hepatitis B virus surface antigen (HBsAg) for intramuscular administration. It contains purified HBsAg obtained by culturing genetically engineered Saccharomyces cerevisiae cells, which carry the surface antigen gene of the hepatitis B virus. Each 1-mL adult dose contains 20 g of HBsAg adsorbed on 0.5 mg aluminum as aluminum hydroxide. FDA approved for persons 20 years of age and older for a series of 3 doses on a 0-, 1-, 6-month schedule.
Study NCT02930057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celestone
Description: all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
Study NCT02930057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pulsed radiofrequency treatment
Description: all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
Study NCT02930057 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: pulsed radiofrequency treatment
Description: all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
Study NCT02930057 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
Study NCT02043288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-6004
Description: Study group (3 week/cycle):~NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1
Study NCT02043288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Study group (3 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)~Control group (4 week/cycle):~Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15